



TOP ↑
Industry
NEWS

***BUSY WEEK?** Here are the
TOP INDUSTRY NEWS stories
you might have missed, as
selected by DCAT Editorial
Director Patricia Van Arnum.*

1. Corning Plans \$4-Billion Glass Packaging Investment

Corning, a material-sciences company, plans to invest \$4 billion as part of a new pharmaceutical glass packaging initiative for parenteral drugs with a first-phase investment of \$500 million. The investment includes funding for manufacturing expansions in New Jersey, New York, and a to-be-determined location in the southeast US. [Read More](#)

2. Stada Recommends Revised Takeover Bid to Shareholders

The Executive Board and the Supervisory Board of Stada Arzneimittel AG, a generic and over-the-counter drug company, have recommended for shareholder approval a revised offer for EUR 66.25 (\$77.11) per share for the company from Nidda Healthcare Holding AG, the acquiring company of the private investment firms, Bain Capital and Cinven Partners. The firms had made an offer earlier this year that was rejected by shareholders. [Read More](#)

3. Boehringer Ingelheim Plans \$217-Million Mfg Expansion in US

Boehringer Ingelheim has announced a \$217-million investment to upgrade and expand its biomanufacturing facility in Fremont, California. [Read More](#)

4. AstraZeneca, Merck & Co. in Drug Pact Worth Up to \$8.5 Billion

AstraZeneca and Merck & Co. have formed a global strategic oncology collaboration to co-develop and co-commercialize AstraZeneca's cancer drug, Lynparza (olaparib), for multiple cancer types in a deal worth up to \$8.5 billion, including \$1.6 billion upfront. [Read More](#)

5. Endo to Restructure Manufacturing Network

Endo International, a specialty pharmaceutical and generic-drug company, plans to cease operations and close its manufacturing and distribution facilities in Huntsville, Alabama. The company made the decision after completing a review of its manufacturing network. [Read More](#)

6. Merck & Co. Launches Biosimilar to J&J's Remicade

Merck & Co. has launched in the US Renflexis (infliximab-abda), a biosimilar of Johnson & Johnson's (J&J) anti-inflammatory drug, Remicade (infliximab). Remicade is the top-selling drug in J&J's pharmaceuticals division with 2016 sales of \$6.97 billion. [Read More](#)

7. Sanofi in Antibody Fragment Deal Worth Up to \$2.8 billion

Sanofi has entered into a research collaboration and global exclusive licensing agreement with Ablynx, a biopharmaceutical company focused on developing and commercializing therapeutics based on single-domain antibody fragments, in a deal worth up to \$2.8 billion. [Read More](#)

8. Alembic Inaugurates New Drug-Product Manufacturing Facility

Alembic Pharmaceuticals, a Mumbai, India-headquartered pharmaceutical company, has inaugurated a new manufacturing facility focused on anticancer treatments at its site in Panelave, Halol, Gujarat, India. [Read More](#)

9. Mitsubishi Tanabe To Acquire Parkinson's Drugs for \$1.1 Billion

Mitsubishi Tanabe Pharma has agreed to acquire NeuroDerm, a pharmaceutical company that develops formulation technology and drug-device combinations for Parkinson's disease, for \$1.1 billion. [Read More](#)

10. [Lilly, Incyte in Late-Stage Setback for Arthritis Drug](#)

Eli Lilly and Company and Incyte report that the resubmission of their new drug application to the FDA for baricitinib, a drug to treat moderate-to-severe rheumatoid arthritis, will be delayed beyond 2017. The news is part of *DCAT Value Chain Insights Pipeline News*. [Read More](#)

***The DCAT organization is happy to provide this service to its members each Friday.
Have a great weekend!***

About Top Industry News

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.



The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



One Union Street, Suite 208, Robbinsville, NJ 08691
Local: +1.609.208.1888 · Toll Free: +1.800.640.DCAT(3228) · Fax: +1.609.208.0599
www.dcat.org

Drug, Chemical, & Associated Technologies Association, One Union Street,
Suite 208, Robbinsville, NJ 08691

[SafeUnsubscribe™ {recipient's email}](#)

[Forward this email](#) | [Update Profile](#) | [About our service provider](#)

Sent by dcatnews@dcat.org